ArticleNeurological research and practice2026
Discharge outcomes of intravenous alteplase 4.5-24 hours after symptom onset in selected patients with acute ischemic stroke: a propensity score-matched real-world study.
Article in Neurological research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEvidence for alteplase 4.5-24 h after acute ischemic stroke (AIS) onset remains limited in routine practice. We examined associations between late-window intravenous thrombolysis (IVT) and discharge outcomes in selected patients.
methodsWe analyzed China Stroke Center Alliance patients arriving 4-23.5 h after onset. Alteplase-treated patients were matched 1:1 to non-IVT patients using propensity scores. The primary outcome was modified Rankin Scale (mRS) 0-1 at discharge. Secondary and safety outcomes included mRS 0-2, registry-recorded in-hospital intracranial hemorrhage (ICH), mortality, discharge against medical advice (DAMA), and mortality or DAMA.
resultsAmong 137,157 eligible AIS patients, 874 received IVT and were matched to 874 non-IVT patients. Median onset-to-needle time was 6.05 h (interquartile range 5.12-10.04); 48.4%, 23.7%, 6.6%, and 21.3% were treated at 4.5-<6, 6-<9, 9-<12, and 12-24 h, respectively. IVT was associated with higher rates of mRS 0-1 (30.4% vs. 17.0%, odds ratio [OR] 2.14, 95% confidence interval [CI], 1.70-2.69, p < 0.001) and mRS 0-2 (65.4% vs. 58.1%; OR, 1.36; 95% CI, 1.12-1.66, p = 0.002). In-hospital ICH was more frequent (1.7% vs. 0.6%, OR 3.04, 95% CI, 1.10-8.39, p = 0.03), whereas DAMA was less frequent (5.7% vs. 8.8%, OR 0.63, 95% CI, 0.44-0.92, p = 0.02). Length of hospital stay, mortality, and mortality or DAMA did not differ significantly.
conclusionsLate-window alteplase was associated with better discharge function but more registry-recorded ICH in selected patients. Because symptomatic status, hemorrhage subtype, severity, and fatality were unavailable, hemorrhagic safety remains incompletely characterized. These observational findings require cautious interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.